Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:

Two China Companies to Bid in $765 Million Auction for I-Med Radiology of Australia

publication date: Nov 1, 2017

Two China healthcare companies -- Tonghua Golden-Horse Pharma and Golden Meditech Holdings -- will submit bids in the second round of an auction to acquire I-MED Radiology, an Australian diagnostics service company. The bidding is expected to top $765 million. With nearly 200 clinics across Australia, I-MED is the nation’s largest diagnostic imaging services provider with 18% of the market. In 2016, I-MED reported $467 million in sales and $77 million in EBITDA. More details....

Stock Symbols: (SHZ: 000766) (HK: 0801)

Share this with colleagues:

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio Event
Beijing and Digital
September 13-16, 2022
ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
July 27-31, 2022